These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35072888)

  • 81. Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA.
    Singh D; Fabbri LM; Vezzoli S; Petruzzelli S; Papi A
    Int J Chron Obstruct Pulmon Dis; 2019; 14():531-546. PubMed ID: 30880943
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Critical Error Frequency and the Impact of Training with Inhalers Commonly used for Maintenance Treatment in Chronic Obstructive Pulmonary Disease.
    Collier DJ; Wielders P; van der Palen J; Heyes L; Midwinter D; Collison K; Preece A; Barnes N; Sharma R
    Int J Chron Obstruct Pulmon Dis; 2020; 15():1301-1313. PubMed ID: 32606640
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Comparing Clinical Outcomes of Tiotropium/Olodaterol, Umeclidinium/Vilanterol, and Indacaterol/Glycopyrronium Fixed-Dose Combination Therapy in Patients with Chronic Obstructive Pulmonary Disease in Taiwan: A Multicenter Cohort Study.
    Hsieh MJ; Chen NH; Cheng SL; Tao CW; Wei YF; Wu YK; Chan MC; Liu SF; Hsu WH; Yang TM; Lin MS; Liu CL; Kuo PH; Tsai YH
    Int J Chron Obstruct Pulmon Dis; 2022; 17():967-976. PubMed ID: 35510163
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Recent advances in COPD disease management with fixed-dose long-acting combination therapies.
    Bateman ED; Mahler DA; Vogelmeier CF; Wedzicha JA; Patalano F; Banerji D
    Expert Rev Respir Med; 2014 Jun; 8(3):357-79. PubMed ID: 24802656
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal.
    Vanfleteren L; Fabbri LM; Papi A; Petruzzelli S; Celli B
    Int J Chron Obstruct Pulmon Dis; 2018; 13():3971-3981. PubMed ID: 30587953
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Which LABA/LAMA should be chosen in COPD patients in real life?
    Sposato B; Petrucci E; Serafini A; Lena F; Lacerenza LG; Montagnani A; Alessandri M; Cresti A; Scala R; Rogliani P; Ricci A; Perrella A; Scalese M
    Pulm Pharmacol Ther; 2021 Dec; 71():102076. PubMed ID: 34530132
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Cost-Effectiveness of Dual Bronchodilator Indacaterol/Glycopyrronium for COPD Treatment in China.
    Gong S; Hu H; Zhao K; Yang T
    Int J Chron Obstruct Pulmon Dis; 2021; 16():433-441. PubMed ID: 33654393
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Efficacy, Safety, and Systemic Exposure of Once-Daily Indacaterol Acetate in Pediatric Asthma: A Randomized, Double-Blind, Controlled Dose-Finding Study.
    Sekerel BE; Nell H; Laki I; Pak T; Contreras E; Kolarz A; D'Andrea P; Manga V; Jain M; Vaidya S; Valentin M; Sen B
    Clin Drug Investig; 2023 Sep; 43(9):719-728. PubMed ID: 37682405
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Plackett-Burman and face-centered composite designs for development and optimization of chromatographic method for the simultaneous determination of glycopyrronium, indacaterol and mometasone in their fixed dose combination inhaler - Green profile assessment.
    Youssef YM; Mahrouse MA; Mostafa EA
    J Pharm Biomed Anal; 2023 Sep; 234():115553. PubMed ID: 37399700
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Digitally monitored inhaled therapy: a 'smart' way to manage severe asthma?
    Sykes DL; See YY; Chow ECY; Crooks MG; Cummings H; Robinson M; Watkins K; Thompson J; Overton K; Riches C; Faruqi S
    J Asthma; 2024 Sep; 61(9):970-975. PubMed ID: 38323583
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Pharmacokinetics of QMF149 in Japanese versus Caucasian subjects: an open-label, randomized phase I study.
    Shimada S; Vaidya S; Khindri S; Tashiro N; Cheng Y; Hara H; Majumdar T; Woessner R; Furihata K; Kobayashi K
    Int J Clin Pharmacol Ther; 2015 May; 53(5):398-407. PubMed ID: 25740265
    [TBL] [Abstract][Full Text] [Related]  

  • 92. The Role of Long-Acting Antimuscarinic Agents in the Treatment of Asthma.
    Arslan B; Çetin GP; Yilmaz İ
    J Aerosol Med Pulm Drug Deliv; 2023 Aug; 36(4):189-209. PubMed ID: 37428619
    [TBL] [Abstract][Full Text] [Related]  

  • 93. The Role of ICS/LABA Fixed-Dose Combinations in the Treatment of Asthma and COPD: Bioequivalence of a Generic Fluticasone Propionate-Salmeterol Device.
    Tashkin DP; Ohar JA; Koltun A; Allan R; Ward JK
    Pulm Med; 2021; 2021():8881895. PubMed ID: 33815843
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Design of Experiment-Based Green UPLC-DAD Method for the Simultaneous Determination of Indacaterol, Glycopyrronium and Mometasone in their Combined Dosage Form and Spiked Human Plasma.
    Tarek M; Ghoniem NS; Hegazy MA; Wagdy HA
    J Chromatogr Sci; 2024 Aug; 62(7):676-685. PubMed ID: 37635399
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Interactions between glycopyrronium and indacaterol on cholinergic neurotransmission and contractile response in bovine trachealis.
    Baroffio M; Barisione G; Brusasco V
    Respir Res; 2017 Jul; 18(1):145. PubMed ID: 28754132
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Real-world comparative effectiveness of three single-inhaler dual bronchodilators for the treatment of COPD.
    Li J; Dell'Aniello S; Ernst P; Suissa S
    Eur Respir J; 2023 Aug; 62(2):. PubMed ID: 37343975
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Single inhaler triple therapy (SITT) in asthma: Systematic review and practice implications.
    Agusti A; Fabbri L; Lahousse L; Singh D; Papi A
    Allergy; 2022 Apr; 77(4):1105-1113. PubMed ID: 34478578
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Efficacy of Indacaterol/Glycopyrronium in Patients with COPD Who Have Increased Dyspnea with Daily Activities.
    Mahler DA; Keininger DL; Mezzi K; Fogel R; Banerji D
    Chronic Obstr Pulm Dis; 2016 Sep; 3(4):758-768. PubMed ID: 28848901
    [No Abstract]   [Full Text] [Related]  

  • 99. Modelling the Cost-Effectiveness of Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone Using a Novel Markov Exacerbation-Based Approach.
    Lakhotia B; Mahon R; Gutzwiller FS; Danyliv A; Nikolaev I; Thokala P
    Int J Chron Obstruct Pulmon Dis; 2020; 15():787-797. PubMed ID: 32368025
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Differences in Pulmonary Function Improvement after Once-Daily LABA/LAMA Fixed-Dose Combinations in Patients with COPD.
    Huang WC; Chen CY; Liao WC; Wu BR; Chen WC; Tu CY; Chen CH; Cheng WC
    J Clin Med; 2022 Dec; 11(23):. PubMed ID: 36498738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.